Abstract 1436P
Background
To understand if there is sex disparity in survival outcomes among the patients with advanced gastric adenocarcinoma (GAC), gastroesophageal junction adenocarcinoma (GEJAC), and esophageal adenocarcinoma (EAC).
Methods
The study included patients from Kaiser Permanente Northern California with metastatic or relapsed EAC, GEJAC and GAC whose tumor underwent next-generation sequencing. We used Cox regression modeling to examine association of male and female patients with overall survival (OS) adjusting for demographics, performance status, Charlson comorbidity index, receipt of chemotherapy, and six most common genomic alterations including HER2 overexpression/amplification, p53, KRAS, CDKN2A, PIK3CA co-mutation and Myc amplification.
Results
Among 875 eligible patients, 275 were female and 600 were male. OS for male versus female patients did not appear substantially different for the entire cohort (HR = 0.87; [95% CI, 0.74-1.03]), for EAC (HR = 1.0; [95% CI, 0.57-1.74]) and GEJAC (HR = 1.14; (95% CI, 0.77-1.67]) subgroups. However, OS of male versus female patients with GAC appeared substantially better (HR = 0.75; [95% CI, 0.60-0.93]). In addition, this substantial OS difference was preserved regardless of HER2 status, CDKN2A and PIK3CA mutation or Myc amplification. Intriguingly, despite overall there was no OS difference between male versus female GAC patients regardless of p53 mutation status, however, among GAC patients with a p53 mutation, male had substantially better OS than female patients only if tumor carried non-gain-of-function (non-GOF, HR = 0.59; [95% CI, 0.41-0.85]) but not gain-of-function mutation (GOF, HR = 1.46; [95% CI, 0.74-2.87]).
Conclusions
We have found that male versus female GAC patients had substantially better overall survival. Most intriguingly, the survival difference among patients with mutp53 was only observed if tumor carried mutp53 non-GOF. Our results for the first time identified a sex disparity in survival outcomes that is associated with a common molecular lesion and can have important implications in understanding the biology of GAC and in clinical practice for prognostic stratification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
1448P - IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Presenter: Christelle de la Fouchardiere
Session: Poster session 18
1449P - Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Presenter: Markus Moehler
Session: Poster session 18
1450P - Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Presenter: Georg Martin Haag
Session: Poster session 18
1453P - A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Presenter: Nan Bi
Session: Poster session 18
1454P - An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Presenter: Akihito Kawazoe
Session: Poster session 18
1455P - Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer: A prospective, single-arm, phase II clinical trial
Presenter: Pengfei Zhang
Session: Poster session 18
Resources:
Abstract